Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Artelo Biosciences (NASDAQ: ARTL) announced that its CEO, Gregory Gorgas, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Artelo Biosciences (NASDAQ: ARTL) announced that its CEO, Gregory Gorgas, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be available on demand for registered attendees starting September 13 at 7:00 AM ET. Artelo aims to develop therapeutics targeting lipid signaling pathways, focusing on unmet medical needs in areas such as cancer and pain management. For more details, the company's presentation can be accessed via its investor relations webpage.
Details
News Market Reaction – ARTL
The recorded move for ARTL in the trading session of this news was -3.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOLANA BEACH, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas, President and Chief Executive Officer of Artelo Biosciences, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.
Artelo’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021 at 7:00 AM Eastern Time. Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference.
The webcast of the Company’s presentation can also be accessed here and on the investor relations section of Artelo's website at https://ir.artelobio.com/ as of 7:00 AM Eastern Time on Monday, September 13, 2021.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that target lipid signaling pathways, including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven pharmaceutical executives collaborating with highly respected researchers and technology experts, Artelo applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.